Trop J Nat Prod Res, June 2022; 6(6):915-920 **ISSN 2616-0684 (Print)**
ISSN 2616-0692 (Electronic)

Tropical Journal of Natural Product Research

Available online at https://www.tjnpr.org

Original Research Article

Analysis of Potential Poly (ADP-Ribose) Polymerase 2 (PARP2) Inhibitor in Nyale Worm (*Eunice sp.*) Extract for Ovarian Cancer: An *In Silico* Approach

Putu D. Arjita[1]*, Rozikin Rozikin[1,2], Gede A. Adnyana[2], Putu B.A. Saputra[2], Sabrina I. Zoraya[3]

[1]*Herbal Medicine and Nutrigenomic Department of the Faculty of Medicine, Al-Azhar Islamic University. Mataram, West Nusa Tenggara 83232, Indonesia*
[2]*Metabolic and Antioxidant Department of the Faculty of Medicine, Al-Azhar Islamic University. Mataram, West Nusa Tenggara 83232, Indonesia*
[3]*Public Health and Travel Medicine Department of the Faculty of Medicine, Al-Azhar Islamic University. Mataram, West Nusa Tenggara 83232, Indonesia*

ARTICLE INFO

Article history:
Received 16 May 2022
Revised 17 June 2022
Accepted 28 June 2022
Published online 02 July 2022

ABSTRACT

Cancer is an umbrella term for a large group of diseases that are characterized by abnormal cell growth and adjacent tissue or organ invasion. One of the most common cancers in Indonesia is ovarian cancer. Recently, PARP enzyme inhibitor used as a therapy for cancer, including ovarian cancer, has become more common. Apart from the standard PARP inhibitor drug, natural resources are also found to have high potential for cancer therapy. Marine biotas are known for their capability to produce biomolecules which can inhibit the cell mitosis of their rivals or predators. One of the marine biotas that are commonly consumed in Lombok Island is Nyale worm. This research aimed to analyze the potential PARP, particularly PARP2, inhibitor compounds in Nyale worm extract for ovarian cancer by using molecular docking with *in silico* approach. Compounds identification was conducted by using gas chromatography-mass spectrometry (GC-MS) and molecular docking was done with PyRx v.0.8 software. There were three potential PARP2 inhibitor compounds, tricyclo[10.2.1.02,11]pentadeca-4,8-diene, tricyclo[8.6.0.02,9]hexadeca-3,15-diene, and linoleic acid. The binding affinity energy of these three compounds were lower compared with that of the native ligand 3-aminobenzamide. The lower value of the energy means greater molecular binding stability and PARP2 inhibition mechanism.

Keywords: DNA repair, Nyale worm, Ovarian cancer, PARP, PARP2 inhibitor.

Introduction

Cancer is an umbrella term for a large group of diseases that are characterized by abnormal cell growth and adjacent tissue or organ invasion.[1] One of the most common cancers in Indonesia is ovarian cancer. As of 2018, there were 14,896 new cases of ovarian cancer making it the tenth disease with the most new cases in Indonesia according to Globocan data.[2] With a total of 9,581 deaths, ovarian cancer is also the seventh cancer with the highest number of deaths.[3]
Anticancer therapy targeting Poly(ADP-ribose) polymerase (PARP) enzyme was originally proposed by Mendel. PARP enzyme detects the DNA single-strand break (SSB) and causes DNA repair in cancer cells through base exicional repair (BER) mechanism.[4] PARP uses NAD^+ that is transferred to the glutamate, aspartate, and lysine residues acceptor to catalyze ADP-ribose for auto-modification. This facilitates DNA repair through the formation of chromatin structures by replacing the histone and signaling the DNA repair complex protein. There are 17 enzymes of the PARP superfamily in humans, including PARP1 and PARP2.[5,6] Recently, PARP enzyme inhibitor use as a therapy for cancer, including ovarian cancer, has become more common.[6,7,8] An orally-administered PARP inhibitor standard drug, 3-aminobenzamide, is effective in enhancing the damage of the cancer cell DNA.[6, 9]

*Corresponding author. E mail: iputudedyarjita@gmail.com
Tel: +62 823-3929-1515

Citation: Arjita IPD, Rozikin R, Adnyana IGA, Saputra IPBA, Zoraya SI. Analysis of Potential Poly (ADP-Ribose) Polymerase 2 (PARP2) Inhibitor in Nyale Worm (*Eunice sp.*) Extract for Ovarian Cancer: An In Silico Approach. Trop J Nat Prod Res. 2022; 6(6):915-920. doi.org/10.26538/tjnpr/v6i6.16

Official Journal of Natural Product Research Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria.

Apart from the standard drug, natural resources are also found to have high potential for cancer therapy.
Marine biotas are known for their capability to produce biomolecules which can inhibit the cell mitosis of their rivals or predators.[10, 11] A marine worm, *Hermione hystrix*, is reported to have antimitotic-cytotoxic activity towards sea urchin *Paracentrotus lividus* embrio.[12] Several other marine biotas such as sponges, mollusks, and cyanobacteria are also reported to have anticancer compounds.[13]
Lombok Island is rich in marine biota. One of the renowned marine biotas found in Kuta Mandalika beach, a famous tourism destination in Central Lombok, is Nyale worm. It is commonly consumed by the local community. Nyale worm (*Eunice sp.*) from *Eunicidae* family is a member of Polychaeta class that includes three other species, *Lysidice sp*., *Neanthes*, and *Aphrodite*.[14]
The anticancer properties of Nyale worm have not been widely researched. Therefore, this research aimed to analyze the potential PARP2 inhibitor compounds in Nyale worm extract for ovarian cancer by using molecular docking with *in silico* approach. The compounds were compared with a standard drug for inhibition target mechanism against PARP2 enzyme.

Materials and Methods

Sample collection and extraction
Nyale worms were collected from the coastal waters of Kuta Mandalika,Central Lombok. Dried samples were ground in a mortar and macerated in 250 mL ethanol 96% for 24 hours and n-hexane (99%) for 8 h. The residue was extracted three times with ethanol until it was colorless for ethanol extraction. Evaporator at 68°C was used for the solvent (n-hexane) removal.

Chemistry
Quantitative analysis with gas chromatography-mass spectrometry (GC-MS) Shimadzu 2010 was conducted to identify the bioactive compounds present in Nyale worm extract.

Protein/Macromolecule
PARP2 (GDP: 3KCZ) structure was obtained from rscb.org in the Protein Data Bank (PDB) format. PARP2 structure consisted of two chains, chain A and chain B. Each chain contained inhibitor ligand 3-aminobenzamide. PARP2 PDB structure was prepared using PyMOL 2.5.2.

Ligand and drug screening
Twenty compounds were identified by GC-MS in the Nyale worm extract. The compounds identity were confirm through chemical searched using PubChem database (https://pubchem.ncbi.nlm.nih.gov/). The bioavailability of the compounds was assessed according to Lipinski's Rule of Five using SwissADME (http://www.swissadme.ch/). Assessment of human intestinal absorption (HIA) was conducted with the use of PreADMET predictor (https://preadmet.webservice.bmdrc.org/). Ligands were prepared using Avogadro 1.2.[15]

Molecular docking
Molecular docking of the twenty compounds in Nyale worm extract to the PARP2 protein was done with PyRx v.0.8 software.[16] The molecule binding target area was X: 19.5762, Y: 2.9482, Z: 20.3313 and Dimension (A) X: 11.3241, Y: 8.1201, Z: 10.2827. This was the binding site of 3-aminobenzamide, a widely-used PARP2 inhibitor standard drug. The active binding site on PARP2 was observed in Computed Atlas of Surface Topography of Proteins (CASTp) (sts.bioe.uic.edu/castp/index.html?3kcz).[17] The result of the protein interaction and ligand binding residue identification was visualized with PyMOL 2.5.2 and Discovery Studio R17.

Results and Discussion

PARP2 inhibitor mechanism for cancer cell
PARP2 working mechanism in Figure 3 shows that DNA repair is a potential target to kill ovarian cancer cell.[18] The SSB is often found in proliferating cells. The PARP2 inhibitor affects BER, preventing the DNA repair to occur. The SSB then turns into double-strand break (DSB) leading to inhibition of cell proliferation. It may also affect the cell recombinant if the homologous recombination deficiency (HRD) is present. This condition renders the DSB irreparable, inducing cell apoptosis.[19]
PARP2 was found to have NAD^+ cofactor (denoted by arrow). NAD^+ has a pivotal role in DNA repair process. NAD^+ breaks down into nicotinamide and ADP-ribose to form poly(ADP-ribose) (PAR) which binds to the DNA repair protein acceptor.[20] Previous studies reported that inhibiting NAD^+ significantly hampered the DNA repair by PARP2, leading to cell apoptosis.[21,22]
The binding affinity of 3-Aminobenzamide was -6.6 kcal/mol. This value indicated the energy needed to bind to the PARP2 receptor. The lower the value, the higher the possibility of a compound to tightly bind to the PARP2 receptor.[23]

Human intestinal absorption (HIA)
Percentage of HIA (% HIA) tells the absorbability of the compounds in the small intestine. Table 1 indicates that the compounds in Nyale worm extract had high absorption level (HIA > 90%). This means that the compounds have good oral absorption profile and can reach the ovarian cancer cell receptor if administered orally. Thus, oral administration can increase the efficacy of the compounds.[24]

Lipinski's rule of five
Assessment according to Lipinski's Rule of Five parameter before docking can ensure the ability of the compound to reach the appropriate receptor binding site.[25,26]



Figure 1: Some the compounds identified in Nyale worm (*Eunice sp.*)



Figure 2: Visualization of the inhibitor compounds against PARP2

Molecular docking

There were three potential PARP2 inhibitor compounds (Figure 1**)**, tricyclo[10.2.1.0^{2,11}]pentadeca-4,8-diene, tricyclo[8.6.0.0^{2,9}]hexadeca-3,15-diene, and linoleic acid (Table 1). Molecular docking can predict the amount of energy generated among two or more interacting or binding molecules.[27] The binding affinity energy of the three compounds were lower compared with that of the native ligand 3-aminobenzamide. Figure 2 shows the visualization of PARP2 where the four compounds bound to the same active site. The lower value of the energy resulting from docking (kcal/mol) means greater molecular binding stability and PARP2 inhibition mechanism.[28]

Interaction between PARP2 and 3-aminobenzamide shown in Table 2 explains its affinity for PARP2 inhibitor. The side chain residue of TYR473 formed pi-alkyl bond with the imidazole ring. The bond between GLU558 and nitrogen atom at the end of the imidazole chain formed two hydrogen bonds. The backbone of TRP427 and HIS428 bound to the nitrogen atom, also forming the hydrogen bonds. The backbone residue of GLY429 and SER470 formed hydrophobic bonds. TYR462 caused an interaction with the cyclic amine substituent (proline) in the benzamidine ring to the backbone of GLY429. The residue of LYS469, TYR462, ALA464, PHE463 formed hydrophobic bonds as well.

The low binding affinity of tricyclo[8.6.0.0.0^{2,9}]hexadeca-3,15-diene results from interaction of TYR473 residue with the cyclooctane ring of the inhibitor ligand. This residue functioned as a bridge for the bond between TYR462 and inhibitor. LYS469 and ALA464 also bound to the cyclooctane ring, forming pi-alkyl bond. TYR462 residue had a key role in the binding to the side chain of cyclooctane ring and in determining the binding of the inhibitor compound.

Similarly, the interaction between the inhibitor compound tricyclo[10.2.1.0^{2,11}]pentadeca-4,8-diene and the PARP2 receptor, indicates that TYR473 bound to the cyclodecane ring, forming two pi-alkyl bonds. Likewise, residue TYR462 formed pi-alkyl bonds withtricyclo[10.2.1.0^{2,11}]pentadeca-4,8-diene causing low and stable binding affinity energy.

The interaction between the GLY 492 residue with the oxygen molecules contained in the linoleic acid causes the formation of hydrogen interactions. Hydrogen interactions are also formed at the SER470 residue that binds the H atoms contained in the linoleic acid.[29] TYR473, LYS469, and ALA464 bound to the linoleic chain to form pi-alkyl bonds. Linoleic acid, also known as omega-6, is reported to have anticancer properties.[30] Study by Zhang stated that linoleic acid could deliver a significant improvement in breast cancer treatment.[31] Another study reported that conjugated linoleic acid has antiproliferative activity and is able to activate the cell death pathway.[32]

Residues TYR473 and TYR462 were actively involved in the interaction with the three inhibitors from the Nyale worm extract. The result of the interactions of the inhibitor compounds from the Nyale worm extract compares favourably with the commercially used native ligand with respect to the similarity of the binding domains.



Figure 3: PARP2 inhibitor working mechanism

Table 1: Identification of the potential PARP2 inhibitor compounds contained in Nyale worm extract based on their bioavailability and HIA.

No	Compound Name	Molecular Formula	Da	H-donor	H-acceptor	LogP	HIA (%)	Binding Affinity (kcal/mol)
1	Tricyclo[8.6.0.0^{2,9}]hexadeca-3,15-diene	$C_{16}H_{24}$	202.34	0	0	4.02	100	-8.8
2	3-Aminobenzamide (native ligand)	$C_7H_8N_2O$	136.15	2	1	0.32	90.98	-6,6
3	Margaric acid	$C_{17}H_{34}O_2$	270,45	1	2	5,57	98,40	-6,2
4	9-Octadecenal	$C_{18}H_{34}O$	266,46	0	1	5,94	100	-6,1
5	Myristic acid	$C_{14}H_{28}O_2$	228,37	2	1	4,45	978.483	-5,9
6	Pentadecylic acid	$C_{15}H_{30}O_2$	242,40	1	2	4,84	98,11	-5,9
7	Stearic acid	$C_{18}H_{36}O_2$	284,48	1	2	5,93	98,44	-6,2
8	Linoleic acid	$C_{18}H_{32}O_2$	280,45	1	2	5,45	98,37	-6,7
9	Palmitic acid	$C_{16}H_{32}O_2$	256,42	1	2	5,20	98,29	-6.1
10	Methyl myristate	$C_{15}H_{30}O_2$	242,40	2	0	4,81	100	-5,8
11	Ethyl arachidonate	$C_{22}H_{36}O_2$	332,52	0	2	6,42	100	-5,9
12	Octadec-9-enoic acid	$C_{18}H_{34}O_2$	282.46	1	2	5,71	98.43	-6.6
13	Benzene, 1,2-dimethyl-	$C_6H_4(CH_3)_2$	106.17	0	0	2.83	100	-5.6
14	Hexadecanoic acid	$C_{18}H_{36}O_2$	284,48	0	2	5,79	100	-6.0
15	Tricyclo[10.2.1.0^{2,11}]pentadeca-4,8-diene	$C_{15}H_{22}$	202.34	0	0	4.02	100	-8.4
16	Methyl palmitate	$C_{17}H_{34}O_2$	270.45	0	2	5.54	100	-5.9
17	Ethyl myristate	$C_{16}H_{32}O_2$	256, 42	0	2	5,17	100	-6.0
18	Ethyl palmitate	$C_{18}H_{36}O_2$	284.48	2	0	5.90	100	-5.9
19	Methyl stearate	$C_{19}H_{38}O_2$	298.50	0	2	6.24	100	-6,3
20	Ethyl stearate	$C_{20}H_{40}O_2$	312,53	0	2	6,71	100	-5,9
21	Dythol	$C_{27}H_{46}O$	386,65	1	1	6,67	100	-3.1

Table 2: Interaction between compounds contained in Nyale worm extract and PARP2

No.	Compound Name	Molecular Visualization	Interaction
1.	Tricyclo[10.2.1.0^{2,11}]pentadeca-4,8-diene		TYR473, TYR462, GLU558, LYS 469, ALA 464, SER 470, GLY 429, PHE 463, HIS 428
2	Tricyclo[8.6.0.0^{2,9}]hexadeca-3,15-diene		TYR462, TYR473, LYS469, ALA464, TYR455, GLN332, HIS428, PHE463, GLY429, SER470

3	Linoleic acid		ALA464, TYR473, GLY429, HIS470, MET429, SER470, TRP427, GLY454, PHE463, TYR462, TYR455,
4	3-Aminobenzamide		TYR473, GLU558, HIS428, TRP427, LYS469, TYR462, ALA464, SER470,

Conclusion

This research confirms the anticancer properties in Nyale worm by analyzing the potential PARP2 inhibitor compounds in the worm extract through the use of molecular docking with *in silico* approach. Future studies in developing anticancer drug from Nyale worm extract are encouraged.

Conflict of Interest

The authors declare no conflict of interest.

Authors' Declaration

The authors hereby declare that the work presented in this article is original and that any liability for claims relating to the content of this article will be borne by them.

Acknowledgements

This research was funded by Yayasan Pesantren Al-Azhar.

References

1. Gerner EW, Bruckheimer E, Cohen A. Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer. J Biol Chem. 2018;293(48):18770-18778.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424.
3. Mulawardhana P, Hartono P, Nugroho H, Ayuningtyas A. Death of 43 Indonesian women with ovarian cancer: A case series. Int J Surg Case Rep. 2021; 78:391-396.
4. Pavlova AV, Kubareva EA, Monakhova MV, Zvereva MI, Dolinnaya N. Impact of G-Quadruplexes on the Regulation of Genome Integrity, DNA Damage and Repair. Biomol. 2021; 11(9):1284.
5. Langelier MF, Eisemann T, Riccio AA, Pascal J. PARP family enzymes: regulation and catalysis of the poly (ADP-ribose) posttranslational modification. Curr Opin Struct Biol. 2018;53:187-198.
6. Curtin NJ and Sharma RA. PARP inhibitors for cancer therapy: Humana Press,Cham; 2015; 553-579p.
7. Mirza M, Coleman R, González MA, Moore K, Colombo N, Ray CI, Pignata S. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann. Oncol. 2020; 31(9):1148-1159.
8. Okunlola FO, Akawa OB, Soliman M. Could the spanning of NAM-AD subsites by poly (ADP ribose) polymerase inhibitors potentiate their selective inhibitory activity in breast cancer treatment Insight from biophysical computations. Mol Simul. 2022; 48(2):131-139.
9. Loibl S, Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober, Jens G, Mehra VM, Gunter M, David S, Danielle W, Norman M, Kristi PL, Jose JMF, Otto R, Priya S, Fraser L, Xuan G, Charles E. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018; 19(4):497-509.
10. Saeed AF, Su J, Ouyang S. Pharmacotherapy marine-derived drugs: Recent advances in cancer therapy and immune signaling. Biomed Pharmacother. 2021; 134:111091.
11. Serranodel VA, Reina OC, Benedi A, Anel A, Naval J, Marzo I. Future prospects for mitosis-targeted antitumor therapies. Biochem Pharmacol. 2021; 190:114655.
12. Coutinho M, Teixeira VL, Santos CS. A review of "Polychaeta" chemicals and their possible ecological role. J Chem Ecol. 2018; 44(1):72-94.
13. Barreca M, Spanò V, Montalbano A, Cueto M, Díaz Marrero AR, Deniz I, Erdoğan A, Lukić L, Moulin C, Taffin E. Marine anticancer agents: An overview with a particular focus on their chemical classes. Mar Drugs. 2020; 18(12):619.
14. Bachtiar I and Odani S. Revisiting the Spawning Pattern of Nyale Worms (Eunicidae) Using the Metonic Cycle. Ilmu Kelaut. 2021; 26(2)152.

15. Snyder HD and Kucukkal TG. Computational Chemistry Activities with Avogadro and ORCA. J Chem Educ. 2021; 98(4):1335-1341.
16. Trott O and Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010; 31(2):455-461.
17. Tian W, Chen C, Lei X, Zhao J, Liang J. CASTp 3.0: computed atlas of surface topography of proteins. Nucl Acids Res. 2018; 46(W1):W363-W367.
18. Bartoletti M, Musacchio L, Giannone G, Tuninetti V, Bergamini A, Scambia G, Lorusso D, Valabrega G, Mangili G, Puglisi F. Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. Cancer Treat Rev. 2021; 101:102298.
19. Zhao S, Tadesse S, Kidane D. Significance of base excision repair to human health. Int Rev Cell Mol Biol. 2021; 364:163-193.
20. Wilk A, Hayat F, Cunningham R, Li J, Garavaglia S, Zamani L, Ferraris DM, Sykora P, Andrews J, Clark J. Extracellular NAD+ enhances PARP-dependent DNA repair capacity independently of CD73 activity. Sci Rep. 2020; 10(1):1-21.
21. Pascal JM. The comings and goings of PARP-1 in response to DNA damage. DNA Repair. 2018; 71:177-182.
22. Bian C, Zhang C, Luo T, Vyas A, Chen S-H, Liu C, Kassab MA, Yang Y, Kong M, Yu X. NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression. Nat Commun. 2019; 10(1):1-14.
23. Hosseini M, Chen W, Xiao D, Wang C. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs. Precis Clin Med. 2021; 4(1):1-16.
24. Chivere VT, Kondiah PP, Choonara YE, Pillay V. Nanotechnology-based biopolymeric oral delivery platforms for advanced cancer treatment. Cancers. 2020; 12(2):522.
25. Sisakht M, Mahmoodzadeh A, Darabian M. Plant-derived chemicals as potential inhibitors of SARS-CoV-2 main protease (6LU7), a virtual screening study. Phytother Res. 2021; 35(6):3262-3274.
26. Narkhede RR, Pise AV, Cheke RS, Shinde SD. Recognition of natural products as potential inhibitors of COVID-19 main protease (Mpro): In-silico evidences. Nat Prod Bioprospect. 2020; 10(5):297-306.
27. Li J, Fu A, Zhang L. An overview of scoring functions used for protein–ligand interactions in molecular docking. Interdiscip Sci. 2019; 11(2):320-328.
28. Das P, Majumder R, Mandal M, Basak P. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (Mpro) from flavonoid based phytochemical constituents of *Calendula officinalis*. J Biomol Struct Dyn. 2021; 39(16):6265-6280.
29. Narkhede RR, Cheke RS, Ambhore JP, Shinde SD, Oncology. The molecular docking study of potential drug candidates showing anti-COVID-19 activity by exploring of therapeutic targets of SARS-CoV-2. Eurasian J Med Oncol. 2020; 4(3):185-195.
30. Cheng G, Zhang X, Chen Y, Lee RJ, Wang J, Yao J, Zhang Y, Zhang C, Wang K, Yu B. Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 (LA-SN38) conjugate in a murine model of colorectal cancer. Colloids Surf B. 2019; 181:822-829.
31. Zhang T, Li M, Yang R, Zhang D, Guan J, Yu J, Yang B, Zhang H, Zhang S, Liu D. Therapeutic efficacy of lipid emulsions of docetaxel-linoleic acid conjugate in breast cancer. Int J Pharm. 2018; 546(1-2):61-69.
32. Słowikowski BK, Drzewiecka H, Malesza M, Mądry I, Sterzyńska K, Jagodziński PPJM. The influence of conjugated linoleic acid on the expression of peroxisome proliferator-activated receptor-γ and selected apoptotic genes in non-small cell lung cancer. Mol Cell Biochem. 2020; 466:65-82.